Sixth-Generation hs-cTnT Improves Early Low-Risk Identification in Suspected MI: JAMA

A new cohort study that the sixth-generation High-sensitivity cardiac troponin T (hs-cTnT) assay, when used with a clinically derived risk-stratification threshold, could double the identification of patients at low risk for myocardial infarction or cardiac mortality at presentation when compared with the fifth-generation assay. These findings suggest potential for improved early triage, though prospective studies are needed to assess real-world impact on clinical practice.

Studies evaluating a sixth-generation high-sensitivity cardiac troponin T assay have identified a threshold that can reliably classify patients as low risk for myocardial infarction (heart attack) without the need for prolonged observation or repeated testing. The findings could significantly streamline care in busy emergency settings while maintaining patient safety.

This prospective multicenter study in Scotland analyzed nearly 1,000 patients in its primary cohort and over 1,700 in external validation between 2022 and 2025. All participants presented to emergency departments with symptoms suggestive of non–ST-segment elevation myocardial infarction.

The key threshold was the patients with troponin levels below 13 ng/L at presentation. Among these individuals, the test demonstrated a negative predictive value of 99.9% and sensitivity of 99.4% for ruling out heart attack or cardiac death within 30 days, which met stringent clinical safety standards.

The impact becomes even clearer when compared to the widely used fifth-generation assay. Using the newer test, 61% of patients in the derivation cohort were classified as low risk at presentation, versus significantly fewer with the older method. In early rule-out pathways, the sixth-generation assay identified more than twice as many patients as low risk of 41% when compared to just 17.4%.

Similar trends held in the larger validation cohort across Czechia, Italy, Poland, Spain, and Switzerland. There, 45.4% of patients fell below the low-risk threshold using the newer test, when compared to only 6.9% with the older assay.

This improvement could transform emergency care by reducing unnecessary hospital admissions, by lowering healthcare costs, and improving patient flow, all without compromising the diagnostic accuracy.

Further prospective studies are imperative before widespread adoption. With cardiovascular disease remaining a leading cause of death globally, faster and more precise triage tools could help clinicians focus resources on patients who need urgent intervention.

Reference:

Thurston, A. J. F., Tew, Y. Y., Lopez-Ayala, P., Koechlin, L., O’Brien, R., Lynch, S., Cooper, J. G., Fujisawa, T., Bima, P., McDermott, M., Tuck, C., Mizerska, M., Highton-Williamson, E., McCurrach, F., Lowry, M. T. H., Doudesis, D., Anand, A., Lee, K. K., Ferry, A. V., … POC-ET and APACE Investigators. (2026). Early rule out of myocardial infarction with a novel high-sensitivity cardiac troponin T assay. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2026.0477